| Autor: |
Lohm G; Department of Radiation Oncology, Johanniter-Hospital Genthin-Stendal, 39576 Stendal, Germany.; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany., Knörnschild F; Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany., Neumann K; Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Budach V; Radiation Oncology Vosspalais, Private Clinic, Voss-St. 44, 10177 Berlin, Germany., Schwartz S; Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.; German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany., Burock S; Clinical Trial Office (Campus Mitte), Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Böhmer D; Department of Radiation Oncology (Campus Benjamin Franklin), Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany. |
| Abstrakt: |
In patients with prostate cancer (PCa), salvage radiotherapy (SRT) for biochemical progression (BP) after radical prostatectomy (RP) improves PCa-specific survival. However, no prospective randomized trials have compared the effect of SRT with untreated patients. In this analysis of 151 patients who received SRT for post-RP BP, we compared their overall survival (OS) with virtual, age-matched controls ( n = 151,000) retrieved from government life tables. We also investigated the risk factors associated with BP and OS and compared the prostate-specific antigen (PSA) doubling times (DTs) before and after SRT for patients with BP. The median follow-up was 9.3 years for BP and 17.4 years for OS. The risk factors significantly affecting BP were Gleason score ( p < 0.001), pre-SRT PSA ( p = 0.003), and negative surgical margins ( p = 0.003). None of these risk factors were associated with OS. In 93 patients with BP after SRT, the median PSADT was significantly prolonged compared with pre-SRT values (3.7 vs. 8.3 months, p < 0.001). The OS did not differ between patients and controls ( p = 0.112), and life expectancy was similar, likely due to the survival benefit of SRT. The prolonged PSADT after SRT further supports the beneficial role of SRT in this patient population. However, subsequent treatments were not systematically recorded, which may have affected the results. |
